Prenatal diagnosis of copy number changes (gains or losses) across the entire genome
Diagnosing chromosomal causes for fetal death
Determining recurrence risk of future pregnancy losses
Determining the size, precise breakpoints, gene content, and any unappreciated complexity of abnormalities detected by other methods such as conventional chromosome and fluorescence in situ hybridization (FISH) studies
Determining if apparently balanced abnormalities identified by previous conventional chromosome studies have cryptic imbalances, since a proportion of such rearrangements that appear balanced at the resolution of a chromosome study are actually unbalanced when analyzed by higher-resolution chromosomal microarray
Assessing regions of homozygosity related to uniparental disomy or identical by descent
Cultures from this specimen will be discarded 10 days after all cytogenetic test results have been reported. If further testing is desired, call the laboratory at 800-533-1710..
A maternal blood sample is requested when ordering this test, see PPAP / Parental Sample Prep for Prenatal Microarray Testing. The PPAP test must be ordered under a different order number than the prenatal specimen.
Maternal cell contamination (MCC) testing will be performed at no additional charge on the maternal blood and fetal tissue to rule out the presence of maternal cells in the product of conception sample.
Testing will not be rejected if maternal blood is not received; however, the possibility of maternal cell contamination cannot be excluded.
A paternal blood sample is desired but not required, see PPAP / Parental Sample Prep for Prenatal Microarray Testing.
If an insufficient sample is received or MCC is identified in the prenatal sample, microarray testing will be performed on cultured material.
If a formalin-fixed, paraffin-embedded specimen is submitted, the test will be cancelled and CMAMT / Chromosomal Microarray, Autopsy/Products of Conception/Stillbirth, Tissue will be added and performed as the appropriate test.
For more information see Frequently Asked Questions: Cytogenetic Testing of Products of Conception by Chromosomal Microarray Analysis
Chromosomal Microarray
Array CGH
Oligonucleotide Array
Oligo Array
Single Nucleotide Polymorphism (SNP) Array
Whole Genome Array
Fetal Demise
Miscarriage
Pregnancy Loss
aCGH (Array Comparative Genomic Hybridization)
CMAMT
A maternal blood sample is requested when ordering this test, see PPAP / Parental Sample Prep for Prenatal Microarray Testing. The PPAP test must be ordered under a different order number than the prenatal specimen.
Maternal cell contamination (MCC) testing will be performed at no additional charge on the maternal blood and fetal tissue to rule out the presence of maternal cells in the product of conception sample.
Testing will not be rejected if maternal blood is not received; however, the possibility of maternal cell contamination cannot be excluded.
A paternal blood sample is desired but not required, see PPAP / Parental Sample Prep for Prenatal Microarray Testing.
If an insufficient sample is received or MCC is identified in the prenatal sample, microarray testing will be performed on cultured material.
If a formalin-fixed, paraffin-embedded specimen is submitted, the test will be cancelled and CMAMT / Chromosomal Microarray, Autopsy/Products of Conception/Stillbirth, Tissue will be added and performed as the appropriate test.
For more information see Frequently Asked Questions: Cytogenetic Testing of Products of Conception by Chromosomal Microarray Analysis
Varies
This test does not detect balanced chromosome rearrangements such as Robertsonian or other reciprocal translocations, inversions, or balanced insertions.
A maternal blood sample is requested when ordering this test (see PPAP / Parental Sample Prep for Prenatal Microarray Testing). Testing will not be rejected if maternal blood is not received; however, the possibility of maternal cell contamination cannot be excluded. The PPAP test must be ordered under a different order number than the prenatal specimen.
A paternal blood sample is desired but not required, see PPAP / Parental Sample Prep for Prenatal Microarray Testing.
If additional molecular genetic or biochemical genetic testing is needed, order CULAF / Culture for Genetic Testing, Amniotic Fluid or CULFB / Fibroblast Culture for Molecular Testing, Chorionic Villi/Products of Conception so that cultures may be set up specifically for use in these tests.
Advise Express Mail or equivalent if not on courier service.
1. Provide a reason for referral with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.
2. Notify the laboratory if the pregnancy involves an egg donor or gestational carrier.
| Question ID | Description | Answers |
|---|---|---|
| CG945 | Reason for Referral | |
| CG946 | Specimen |
Submit only 1 of the following specimens:
Specimen Type: Products of conception or stillbirth
Supplies: Hank's Solution (T132)
Container/Tube: Sterile container with sterile Hank's solution, Ringer's solution, or normal saline
Specimen Volume: 1 cm(3) of placenta (including 50-mg chorionic villi) and 1 cm(3) biopsy specimen of muscle/fascia from the thigh
Collection Instructions:
1. Attempt to identify and send only fetal tissue for analysis.
2. If a fetus cannot be specifically identified, collect 50-mg villus material or tissue that appears to be of fetal origin.
3. If multiple specimen types are sent, send each specimen in a separate container. Multiple specimens received (eg, placenta and fetal thigh) will be ordered under 1 test. All specimens will be processed separately.
Additional Information:
1. Do not send entire fetus.
2. While fresher specimens prepared as described above are preferred, we can attempt analysis on specimens that have been in less-than-ideal conditions.
Specimen Type: Autopsy
Supplies: Hank's Solution (T132)
Container/Tube: Sterile container with sterile Hank's solution, Ringer's solution, or normal saline
Specimen Volume: 1 cm(3) biopsy specimen of muscle/fascia from the thigh
Collection Instructions:
1. Wash biopsy site with an antiseptic soap.
2. Thoroughly rinse area with sterile water.
3. Do not use alcohol or iodine preparations.
4. Biopsy specimens are best taken by punch biopsy to include full thickness of dermis.
Specimen Type: Amniotic fluid
Supplies: Refrigerate/Ambient Shipping Box, 5 lb (T329)
Container/Tube: Amniotic fluid container
Specimen Volume: 20-30 mL
Collection Instructions:
1. Optimal timing for specimen collection is during 14 to 18 weeks of gestation, but specimens collected at other weeks of gestation are also accepted. Provide gestational age at the time of amniocentesis.
2. Discard the first 2 mL of amniotic fluid.
3. Place the tubes in a Refrigerate/Ambient Shipping Box, 5 lb.
4. Fill remaining space with packing material.
Additional Information:
1. Unavoidably, about 1% to 2% of mailed-in specimens are not viable.
2. Bloody specimens are undesirable.
3. Results will be reported and also telephoned or faxed, if requested.
Specimen Type: Chorionic villus
Supplies: CVS Media (RPMI) and Small Dish (T095)
Container/Tube: 15-mL tube containing 15 mL of transport media
Specimen Volume: 50 mg
Collection Instructions:
1. Collect chorionic villus specimen (CVS) by transabdominal or transcervical method.
2. Transfer CVS to a Petri dish containing transport medium (Such as CVS Media [RPMI] and Small Dish).
3. Using a stereomicroscope and sterile forceps, assess the quality and quantity of villi and remove any blood clots and maternal decidua.
Acceptable
Specimen Type: Cultured cells
Container/Tube: T25 flasks with culture media
Specimen Volume: 2 T25 flasks
Specimen Type: Tissue
Supplies: Hank Solution (T132)
Container/Tube: In sterile Hank's solution
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Final Disposition of Fetal/Stillborn Remains (if fetal specimen is sent) (Only for products of conception or stillbirth specimen).
3. Chromosomal Microarray Prenatal Patient Information (T716)
Chorionic villus: 10 mg
Muscle-fascia: 1 cm(3)
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Ambient (preferred) | ||
| Refrigerated | |||
Prenatal diagnosis of copy number changes (gains or losses) across the entire genome
Diagnosing chromosomal causes for fetal death
Determining recurrence risk of future pregnancy losses
Determining the size, precise breakpoints, gene content, and any unappreciated complexity of abnormalities detected by other methods such as conventional chromosome and fluorescence in situ hybridization (FISH) studies
Determining if apparently balanced abnormalities identified by previous conventional chromosome studies have cryptic imbalances, since a proportion of such rearrangements that appear balanced at the resolution of a chromosome study are actually unbalanced when analyzed by higher-resolution chromosomal microarray
Assessing regions of homozygosity related to uniparental disomy or identical by descent
Cultures from this specimen will be discarded 10 days after all cytogenetic test results have been reported. If further testing is desired, call the laboratory at 800-533-1710..
A maternal blood sample is requested when ordering this test, see PPAP / Parental Sample Prep for Prenatal Microarray Testing. The PPAP test must be ordered under a different order number than the prenatal specimen.
Maternal cell contamination (MCC) testing will be performed at no additional charge on the maternal blood and fetal tissue to rule out the presence of maternal cells in the product of conception sample.
Testing will not be rejected if maternal blood is not received; however, the possibility of maternal cell contamination cannot be excluded.
A paternal blood sample is desired but not required, see PPAP / Parental Sample Prep for Prenatal Microarray Testing.
If an insufficient sample is received or MCC is identified in the prenatal sample, microarray testing will be performed on cultured material.
If a formalin-fixed, paraffin-embedded specimen is submitted, the test will be cancelled and CMAMT / Chromosomal Microarray, Autopsy/Products of Conception/Stillbirth, Tissue will be added and performed as the appropriate test.
For more information see Frequently Asked Questions: Cytogenetic Testing of Products of Conception by Chromosomal Microarray Analysis
Chromosomal abnormalities may result in malformed fetuses, spontaneous abortions, or neonatal deaths. Estimates of the frequency of chromosome abnormalities in spontaneously aborted fetuses range from 15% to 60%.
Chromosomal microarray (CMA) studies of products of conception, a stillborn infant, or neonate (autopsy) may provide useful information concerning the cause of fetal loss. In addition, CMA may provide information regarding the recurrence risk for future pregnancy loss and risk of having subsequent children with chromosome anomalies. This is particularly useful information if there is a family history of 2 or more miscarriages or when fetal malformations are evident.
CMA is a high-resolution method for detecting copy number changes (gains or losses) across the entire genome in a single assay and is sometimes called a molecular karyotype.
This CMA test utilizes more than 1.9 million copy number probes and approximately 750,000 single nucleotide polymorphism probes for the detection of copy number changes and regions with absence of heterozygosity. Identification of regions of excess homozygosity on a single chromosome could suggest uniparental disomy that may warrant further clinical investigation when observed on chromosomes with known imprinting disorders. In addition, the detection of excess homozygosity on multiple chromosomes may suggest consanguinity.
An interpretive report will be provided.
Copy number variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.
While many copy number changes observed by chromosomal microarray testing can readily be characterized as pathogenic or benign, there are limited data available to support definitive classification of a subset into either of these categories, making interpretation of these variants challenging. In these situations, a number of considerations are taken into account to help interpret results including the size and gene content of the imbalance, as well as whether the change is a deletion or duplication. Parental testing may also be necessary to further assess the potential pathogenicity of a copy number change. In such situations, the inheritance pattern and clinical and developmental history of the transmitting parent will be taken into consideration.
All copy number variants within the limit of detection classified as pathogenic or likely pathogenic will be reported regardless of size. This includes but is not limited to incidental findings currently recommended for reporting by the American College of Medical Genetics and Genomics.(1) Copy number changes with unknown significance will be reported when at least one protein-coding gene is involved in a deletion greater than 1 megabase (Mb) or a duplication greater than 2 Mb.
The detection of excessive homozygosity may suggest the need for additional clinical testing to confirm uniparental disomy (UPD) or to test for variants in genes associated with autosomal recessive disorders consistent with the patient's clinical presentation that are present in regions of homozygosity. Regions with absence of heterozygosity (AOH) of unknown significance will be reported when greater than 5 Mb (terminal) and 10 Mb (interstitial) on UPD-associated chromosomes. Whole genome AOH will be reported when greater than 5% of the genome.
The continual discovery of novel copy number variation and published clinical reports means that the interpretation of any given copy number change may evolve with increased scientific understanding.
This test does not detect all types and instances of uniparental disomy.
This test is not designed to detect low-level mosaicism, although it can be detected in some cases.
This test does not detect point alterations, small deletions, or insertions below the resolution of this assay, or other types of variants such as epigenetic changes.
The results of this test may reveal incidental findings unrelated to the original reason for referral. In such cases, studies of additional family members may be required to help interpret the results.
The array was validated by testing 30 direct and cultured samples previously tested using chromosome analysis or fluorescence in situ hybridization analysis. All abnormalities previously identified by another methodology were confirmed.
1. Kalia, S., Adelman, K., Bale, S. et al: Recommendations for reporting of secondary findings in clinical exome and genome sequencing. 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017 Feb;19(2):249-255. doi: 10.1038/gim.2016.190
2. American College of Obstetricians and Gynecologists Committee on Genetics: Committee Opinion No. 581: the use of chromosomal microarray analysis in prenatal diagnosis. Obstet Gynecol. 2013 Dec;122(6):1374-1377. doi: 10.1097/01.AOG.0000438962.16108.d1
3. Society for Maternal-Fetal Medicine (SMFM), Dugoff L, Norton ME, Kuller JA: The use of chromosomal microarray for prenatal diagnosis. Am J Obstet Gynecol. 2016 Oct;215(4):B2-B9. doi: 10.1016/j.ajog.2016.07.016
4. Sahoo T, Dzidic N, Strecker MN, et al: Comprehensive genetic analysis of pregnancy loss by chromosomal microarrays: Outcomes, benefits, and challenges. Genet Med. 2017 Jan;19(1):83-89. doi: 10.1038/gim.2016.69
5. Rosenfeld JA, Tucker ME, Escobar LF, et al: Diagnostic utility of microarray testing in pregnancy loss. Ultrasound Obstet Gynecol. 2015 Oct;46(4):478-486. doi: 10.1002/uog.14866
DNA extracted from autopsy, products of conception, or stillbirth samples is labeled and hybridized to the microarray. Following hybridization, the microarray is scanned, and the intensity of signals is measured and compared to a reference data set. These data are used to determine copy number changes and regions of excess homozygosity. Chromosomal microarray data alone does not provide information about the structural nature of an imbalance and some abnormal results may be characterized by fluorescence in situ hybridization, limited chromosome analysis, or additional techniques.(Unpublished Mayo method)
Monday through Friday
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
81229
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| CMAPC | Chromosomal Microarray, POC | 94087-4 |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 55253 | Result Summary | 86611-1 |
| 55254 | Result | 62356-1 |
| 55255 | Nomenclature | 62378-5 |
| 55256 | Interpretation | 62357-9 |
| CG945 | Reason for Referral | 42349-1 |
| CG946 | Specimen | 31208-2 |
| 55257 | Source | 48002-0 |
| 55259 | Additional Information | 48767-8 |
| 55260 | Released By | 18771-6 |
| 55258 | Method | 85069-3 |